Immunotherapy for neuroblastoma: Turning promise into reality

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 931-940

  Gray, Juliet C ^a,b   Kohler, Janice A ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Immunology; Immunotherapy; Neuroblastoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CHIMERIC MONOCLONAL ANTIBODY CH14.18; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA VACCINE; ETOPOSIDE; GANGLIOSIDE GD2; GANGLIOSIDE GD2 MONOCLONAL ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HU ANTIGEN; INOTROPIC AGENT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 GANGLIOSIDE GD2 MONOCLONAL ANTIBODY CONJUGATE; INTERLEUKIN 21; ISOTRETINOIN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8 I 131; MYC PROTEIN; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; SURVIVIN; TRASTUZUMAB; TUMOR ANTIGEN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CELL THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FLU LIKE SYNDROME; HUMAN; HYPERPYREXIA; HYPOTENSION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOSTIMULATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; OPSOCLONUS MYOCLONUS SYNDROME; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; TREATMENT DURATION; TUMOR GROWTH;

CHILD; HUMANS; IMMUNOTHERAPY; INSURANCE, HEALTH; MALE; NEUROBLASTOMA;

EID: 71049183183     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22153     Document Type: Review

References (105)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
2. Reynolds CP. Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 2004;8:56-66. (Pubitemid 38787577)
3. Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/ 9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:747-753.
4. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 2008;9:247-256.
5. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 2005;6:649-658. (Pubitemid 41222755)
6. Verdeguer A, Munoz A, Canete A, et al. Long-term results of high-ose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: A report of the Spanish working party for BMTin children (Getmon). Pediatr Hematol Oncol 2004;21:495-504. (Pubitemid 39166872)
7. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-268.
8. Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-4303. (Pubitemid 37248383)
9. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998. (Pubitemid 35363648)
10. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002;188:9-21. (Pubitemid 35398861)
11. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2: 293-299.
12. Klebanoff CA, Gattinoni L, Restifo NP. CD8+T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211: 214-224. (Pubitemid 43882974)
13. Naito Y, Saito K, Shiiba K, et al. CD8+T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-3494. (Pubitemid 28376536)
14. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
15. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995;60:183-189.
16. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-278. (Pubitemid 26044543)
17. Parmiani G, Castelli C, Santinami M, et al. Melanoma immunology: Past, present and future. Curr Opin Oncol 2007;19:121-127. (Pubitemid 46204351)
18. Eggermont AM, Sugarbaker PH. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor. Cancer Detect Prev 1990;14:483-490.
19. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-532. (Pubitemid 24979049)
20. Hellstrom IE, Hellstrom KE, Pierce GE, et al. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci USA 1968;60:1231-1238.
21. Martin RF, Beckwith JB. Lymphoid infiltrates in neuroblastomas: Their occurrence and prognostic significance. J Pediatr Surg 1968;3:161-164.
22. Lauder I, AherneW. The significance of lymphocytic infiltration in neuroblastoma. Br J Cancer 1972;26:321-330.
23. Hughes M, Marsden HB, Palmer MK. Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 1974;34:1706-1711.
24. Gambini C, Conte M, Bernini G, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: Histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003;442:555-562. (Pubitemid 36819249)
25. Raffaghello L, Conte M, De Grandis E, et al. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. Eur J Paediatr Neurol 2009;13:219-223.
26. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonusataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies - A report from the Children's Cancer Group Study. Med Pediatr Oncol 2001;36:612-622. (Pubitemid 32402157)
27. Stefanowicz J, Izycka-Swieszewska E, Drozynska E, et al. Neuroblastoma and opsoclonus-myoclonus-ataxia syndrome - Clinical and pathological characteristics. Folia neuropathologica/ Association of Polish Neuropathologists and Medical Research Centre. Pol Acad Sci 2008;46:176-185.
28. Himoudi N, Yan M, Papanastasiou A, et al. MYCN as a target for cancer immunotherapy. Cancer Immunol Immunother 2008;57: 693-700.
29. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCNstatus in patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 2001;92:2699-2708. (Pubitemid 33049455)
30. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007;25:67-77.
31. Lode HN, Huebener N, Zeng Y, et al. DNA minigene vaccination for adjuvant neuroblastoma therapy. Ann NY Acad Sci 2004;1028:113-121. (Pubitemid 40361815)
32. Carpentier AF, Rosenfeld MR, Delattre JY, et al. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998;4:2819-2824.
33. Coughlin CM, Fleming MD, Carroll RG, et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006;24:5725-5734.
34. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, et al. Cancergermline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 2007;120:67-74. (Pubitemid 44901919)
35. Rodolfo M, Luksch R, Stockert E, et al. Antigen-specific immunity in neuroblastoma patients: Antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003;63:6948-6955. (Pubitemid 37322981)
36. Oberthuer A, Hero B, Spitz R, et al. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004;10:4307-4313. (Pubitemid 38878868)
37. Osajima-Hakomori Y, Miyake I, Ohira M, et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167:213-222. (Pubitemid 40884782)
38. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
39. Pession A, Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets 2005;5:273-283. (Pubitemid 40910560)
40. Ochsenbein AF. Immunological ignorance of solid tumors. Springer Semin Immunopathol 2005;27:19-35.
41. Robinson BW, Lake RA, Nelson DJ, et al. Cross-presentation of tumour antigens: Evaluation of threshold, duration, distribution and regulation. Immunol Cell Biol 1999;77:552-558.
42. Kroczek RA, MagesHW, HutloffA. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 2004;16:321-327.
43. Appleman LJ, Boussiotis VA. T cell energy and costimulation. Immunol Rev 2003;192:161-180.
44. Wolf D, Rumpold H, Wolf AM. Regulatory, T cells in cancer biology: A possible new target for biochemical therapies. Mini Rev Med Chem 2006;6:509-513.
45. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: Back to the future. Semin Cancer Biol 2006;16:137-149.
46. Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007;30:203-214. (Pubitemid 46667800)
47. Wolfl M, Jungbluth AA, Garrido F, et al. Expression ofMHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005;54:400-406.
48. Corrias MV, Occhino M, Croce M, et al. Lack of HLA-class I antigens in human neuroblastoma cells: Analysis of its relationship to TAP and tapasin expression. Tissue Antigens 2001;57:110-117. (Pubitemid 32245231)
49. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471-2478.
50. Raffaghello L, Prigione I, Airoldi I, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004;6:558-568. (Pubitemid 39411093)
51. Bin Q, Johnson BD, Schauer DW, et al. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. Tumour Biol 2002;23:123-129. (Pubitemid 44858303)
52. Rivoltini L, Arienti F, Orazi A, et al. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 1992;34:241-251.
53. Kohler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976;6:511-519.
54. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000;21:403-410.
55. Mirick GR, Bradt BM, Denardo SJ, et al. A review of human antiglobulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004;48:251-257.
56. Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008;8:1151-1158.
57. Kramer K, Gerald WL, Kushner BH, et al. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med Pediatr Oncol 2001;36:194-196.
58. Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16:3053-3060.
59. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti- G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001; 19:4189-4194.
60. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31:261-267.
61. Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004;22:3549-3557. (Pubitemid 41103661)
62. Phase 3 Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue "〉http://clinicaltrials.gov/ct2/show/ NCT00026312〉.
63. Statement from the Children's Oncology Group regarding recently released early results of a clinical trial for children with high-risk neuroblastoma."〉http://www.curesearch.org/uploadedFiles/Statement% 20from%20COG%20regarding%20ANBL0032%2019%2009.PDF〉.
64. Johnson EE, Lum HD, Rakhmilevich AL, et al. Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 2008;57:1891-1902.
65. Lode HN, Xiang R, Dreier T, et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91:1706-1715. (Pubitemid 28110336)
66. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-1759.
67. Castriconi R, Dondero A, Cilli M, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 2007;56:1733-1742. (Pubitemid 47313078)
68. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-833. (Pubitemid 46432004)
69. Joshi AD, Clark EM, Wang P, et al. Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells. J Neuroimmune Pharmacol 2007;2:202-212.
70. Verneris MR, Wagner JE. Recent developments in cell-based immune therapy for neuroblastoma. J Neuroimmune Pharmacol 2007;2:134-139.
71. Rossig C, Bollard CM, Nuchtern JG, et al. Targeting of G(D2)- positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001;94:228-236.
72. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus- associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol 2004;17:401-413. (Pubitemid 39462572)
73. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555. (Pubitemid 26150682)
74. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-1270.
75. Schwinger W, Klass V, Benesch M, et al. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol 2005;16:1199-1206. (Pubitemid 41418325)
76. Truitt RL, Piaskowski V, Kirchner P, et al. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. J Immunother (1991) 1992;11:274-2285.
77. Bauer M, Reaman GH, Hank JA, et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 1995;75: 2959-2965.
78. Pession A, Prete A, Locatelli F, et al. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 1998;78:528-533. (Pubitemid 28360644)
79. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998;92:1941-1949. (Pubitemid 28446683)
80. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998;9:1303-1311. (Pubitemid 28312895)
81. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101:1718-1726. (Pubitemid 36237566)
82. Sandler AD, Chihara H, Kobayashi G, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003;63:394-399. (Pubitemid 36152498)
83. Davidoff AM, Kimbrough SA, Ng CY, et al. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12. J Pediatr Surg 1999;34:902-906; discussion 906-907.
84. Siapati KE, Barker S, Kinnon C, et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 2003;88:1641-1648. (Pubitemid 36713794)
85. Croce M, Meazza R, Orengo AM, et al. Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res 2005;11:735-742. (Pubitemid 40116902)
86. Croce M, Meazza R, Orengo AM, et al. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 2008;57:1625-1634.
87. Shimizu T, Berhanu A, Redlinger RE, Jr., et al. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg 2001;36:1285-1292. (Pubitemid 32705726)
88. Shilyansky J, Jacobs P, Doffek K, et al. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. J Pediatr Surg 2007;42:54-61; discussion 61. (Pubitemid 46037713)
89. Orentas RJ, Schauer D, Bin Q, et al. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001;213:4-13. (Pubitemid 34074965)
90. Caruso DA, Orme LM, Amor GM, et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumorRNA in children with Stage 4 neuroblastoma. Cancer 2005;103:1280-1291.
91. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-8519.
92. Fest S, Huebener N, Weixler S, et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 2006;66:10567-10575. (Pubitemid 44799780)
93. Lode HN, Pertl U, Xiang R, et al. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol 2000;35:641-646.
94. Huebener N, Lange B, Lemmel C, et al. Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett 2003;197:211-217.
95. Gray JC, Johnson PW, Glennie MJ. Therapeutic potential of immunostimulatory monoclonal antibodies. Clin Sci (Lond) 2006;111:93-106. (Pubitemid 44220523)
96. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte- associated antigen 4 blockade and interleukin 2:Aphase I/II study. Ann Surg Oncol 2005;12:1005-1016. (Pubitemid 41660676)
97. Vonderheide RH, FlahertyKT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25: 876-883.
98. Lum HD, Buhtoiarov IN, Schmidt BE, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 2006;79:1181-1192.
99. Turner JG, Rakhmilevich AL, Burdelya L, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells. J Immunol 2001;166:89-94. (Pubitemid 32038420)
100. Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: Towards a new therapy for minimal residual disease. Expert Opin Biol Ther 2008;8:951-968. (Pubitemid 352007006)
101. Cai JY, Tang YJ, Jiang LM, et al. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stemcell transplantation byCD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer 2007;49:952-957.
102. Lyerly HK, Morse MA, Clay TM. Surrogate markers of effective anti-tumor immunity. Ann Surg Oncol 2001;8:190-191.
103. Copier J, Dalgleish AG, Britten CM, et al. Improving the efficacy of cancer immunotherapy. Eur J Cancer 2009;45:1424-1431.
104. Cheung IY, Lo Piccolo MS, Kushner BH, et al. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: Clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003;21:1087-1093.
105. Britten CM, Janetzki S, van der Burg SH, et al. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother 2008;57:285-288.